MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
19.77
-1.21
-5.75%
After Hours: 19.77 0 0.00% 19:30 11/12 EST
OPEN
20.67
PREV CLOSE
20.97
HIGH
21.43
LOW
19.66
VOLUME
857.08K
TURNOVER
--
52 WEEK HIGH
40.65
52 WEEK LOW
13.83
MARKET CAP
1.36B
P/E (TTM)
-7.5084
1D
5D
1M
3M
1Y
5Y
1D
How Early Trial Results At Tyra Biosciences (TYRA) Has Changed Its Investment Story
Simply Wall St · 11h ago
Analysts Are Bullish on Top Healthcare Stocks: Claritev (CTEV), Tyra Bioscience (TYRA)
TipRanks · 16h ago
Tyra Biosciences Is Maintained at Outperform by Wedbush
Dow Jones · 1d ago
Tyra Biosciences Price Target Raised to $57.00/Share From $53.00 by Wedbush
Dow Jones · 1d ago
Nvidia To $200? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 1d ago
Wedbush Maintains Outperform on Tyra Biosciences, Raises Price Target to $57
Benzinga · 1d ago
Oppenheimer Sticks to Their Buy Rating for Tyra Bioscience (TYRA)
TipRanks · 1d ago
Canaccord Genuity Sticks to Their Buy Rating for Tyra Bioscience (TYRA)
TipRanks · 1d ago
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.